Harrow Q1 Revenue Misses on Non-Recurring Adjustment; VEVYE Prescriptions Surge

What happened

Harrow's Q1 2026 revenue of $44.2 million fell short of expectations due to an $8 million non-recurring gross-to-net adjustment related to new VEVYE commercial coverage, obscuring strong underlying demand. Despite an 18% decline in the overall branded dry eye category, VEVYE achieved record new and total prescriptions, positioning it to exceed $100 million in revenue for 2026. IHEEZO unit demand rose 18% year-over-year, with 82% of units from retina accounts, and TRIESENCE unit demand more than doubled for the sixth consecutive quarter. Management expects Q2 revenue between $71 million and $81 million, consistent with full-year guidance of $350-365 million, implying a back-half-weighted profile. While the branded portfolio shows accelerating momentum, the one-time adjustment and continued high leverage (net debt/EBITDA ~8x) mean the company remains far from sustainable profitability.

Implication

The Q1 results highlight that Harrow's branded growth engine is intact with VEVYE, IHEEZO, and TRIESENCE all posting strong demand, which supports the company's ability to hit its $350-365 million full-year revenue target if the back-half ramp materializes. However, the $8 million non-recurring adjustment underscores volatility in revenue recognition and payer negotiation complexity, which could continue to distort quarterly comparisons. High gross margins are offset by heavy interest costs on the 8.625% notes, leaving net income and free cash flow barely positive in best quarters. Regulatory risks around the NJ facility and competitive pressure remain unresolved, limiting moat durability. For the thesis to strengthen, investors need sustained free cash flow and tangible deleveraging, likely several quarters away.

Thesis delta

The Q1 report does not materially alter the fundamental risk-reward profile. Strong VEVYE and IHEEZO prescription trends incrementally support the revenue growth thesis, but the non-recurring adjustment and reaffirmed guidance suggest no inflection to profitability this year. Elevated leverage and regulatory overhang still warrant a cautious stance, and only clear evidence of deleveraging and consistent positive free cash flow would shift the thesis to a more constructive view.